Skip to content

Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation

Treating Primary Progressive Aphasia and Apraxia of Speech With High Definition Transcranial Direct Current Stimulation (HDtDCS-PPA/PAOS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05368350
Enrollment
12
Registered
2022-05-10
Start date
2022-06-01
Completion date
2027-04-16
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apraxia of Speech, Primary Progressive Aphasia

Brief summary

The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., pre-supplementary motor area and left inferior frontal gyrus) thought to aid in memory will improve speech and language difficulties in patients with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS). The primary outcome measures are neuropsychological assessments of speech and language functions, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures.

Detailed description

This pilot study has one treatment arm with open-label treatment and will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to pre-supplementary motor area or left inferior frontal gyrus for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment. All patients with a clinical diagnosis of PPA or PAOS will be assigned to either one of the two open-label arms to receive active tDCS. Primary outcome speech and language measures, secondary neuropsychological and electroencephalography (EEG) measures, and pre-screening assessments for study medical history and contraindications for treatment will be collected prior to the treatment (i.e., baseline). Primary outcome speech and language functions measures and secondary neuropsychological and electroencephalography (EEG) measures will be collected after treatment session 10 and following treatment competition (i.e., 8-week).

Interventions

Other Names: tDCS 1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.

Sponsors

The University of Texas at Dallas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Study participants will be assigned to either Pre-SMA or LIFG arm.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 85 years of age * A formal diagnosis of primary progressive aphasia (nonfluent/agrammatic, semantic, logopenic variants or mixed) and/or progressive apraxia of speech * Capable of understanding and signing an informed consent. Medical information/history, as well as mental status exam and diagnosis provided by referring physician will determine whether or not a caregiver is required to be involved during this process.

Exclusion criteria

* Has an implanted device, such as a pacemaker, metallic cranial implant, or a neurostimulator * Skull defects * Pregnant * A significant history of arrhythmia or epileptic seizures. * Not a native English speaker * Currently receiving speech-language intervention * Unable to communicated verbally

Design outcomes

Primary

MeasureTime frameDescription
The Controlled Oral Word Association TestTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on the Control Word Association Test Benton, L.A., Hamsher, K., \& Sivan, A.B., (1994). Multilingual aphasia examination. Iowa City: AJA Associates.
Category FluencyTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on Category Fluency Benton, L.A., Hamsher, K., \& Sivan, A.B., (1994). Multilingual aphasia examination. Iowa City: AJA Associates.
The Boston Naming TestTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Boston Naming Test (accuracy and speech latency) Kaplan, E., Goodglass, H., \& Weintraub, S., (1983). Boston Naming Test (2nd ed.). Lea \& Febiger: Philadelphia.
Spontaneous speech (content and fluency) of the Western Aphasia Battery-RevisedTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on Spontaneous speech (content and fluency) of the Western Aphasia Battery-Revised Kertesz, Andrew. ( 1982). The Western aphasia battery. New York :Grune \& Stratton.
The Apraxia battery for Adults - 2 (ABA - 2)Treatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on characteristics of articulation of the the Apraxia battery for Adults - 2 Dabul, B. L. (2000). Apraxia Battery for Adults (ABA-2) (2nd edn). Austin, TX: ProEd.

Secondary

MeasureTime frameDescription
The Trail Making Test (Part A & B)Treatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Trail Making Test (Part A \& B) Reitan, R.M., (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Motor Skill., 8, 271-276.
The Digit Span Forward & BackwardTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Digit Span Forward \& Backward Wechsler, D., (2008). Wechsler adult intelligence scale-Fourth Edition (WAIS-IV). San Antonio, TX: NCS Pearson.
The Digit Symbol Substitution TestTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Digit Symbol Substitution Test Wechsler, D., (2008). Wechsler adult intelligence scale-Fourth Edition (WAIS-IV). San Antonio, TX: NCS Pearson.
The Hopkins Verbal Learning Test-RevisedTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Hopkins Verbal Learning Test-Revised Benedict, R. H. B., Schretlen, D., Groninger, L., \& Brandt, J. (1998). The Hopkins verbal learning test-revised: Normative data and analysis of interform and test-retest reliability. Clinical Neuropsychologist, 12, 43-55.
The Rey-Osterrieth Complex Figure TestTreatment change from Baseline to Immediate post, and 8 weeks post treatment completion.Evaluation of treatment differences in change on The Rey-Osterrieth Complex Figure Test Rey, A. (1941). L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). \[The psychological examination in cases of traumatic encepholopathy. Problems.\]. Archives de Psychologie, 28, 215- 285.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJohn Hart, MD

The University of Texas at Dallas

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026